Sebastian J Reinstadler1,2,3, Thomas Stiermaier1,2, Martin Reindl3, Hans-Josef Feistritzer3, Georg Fuernau1,2, Charlotte Eitel1,2, Steffen Desch1,2, Gert Klug3, Holger Thiele1,2, Bernhard Metzler3, Ingo Eitel1,2. 1. Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, Medical Clinic II, University of Lübeck, Ratzeburger Allee 160, Lübeck, Germany. 2. German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Ratzeburger Allee 160, Lübeck, Germany. 3. University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, Innsbruck, Austria.
Abstract
Aims: To evaluate the prognostic value of intramyocardial haemorrhage (IMH) depicted by T2* imaging for risk stratification in ST-elevation myocardial infarction (STEMI) patients in comparison with established cardiac magnetic resonance (CMR) prognosis markers. Methods and results: This multicentre study enrolled 264 patients reperfused within 12 h after symptom onset. CMR was performed within the first week after STEMI to assess left ventricular function and infarct characteristics including IMH. The primary endpoint was a composite of death, reinfarction, and new congestive heart failure (major adverse cardiac events, MACE) at 12 months. MACE occurred in 19 patients (7.2%) showing a higher prevalence of IMH when compared with patients without MACE (47% vs. 21%, P = 0.008). The presence of IMH (n = 60, 23%) was independently associated with MACE after adjusting for clinical risk factors [hazard ratio 2.7, 95% confidence intervals (CIs) 1.1-6.6; P = 0.032] or other CMR prognosis markers (hazard ratio 3.1, 95% CI 1.2-7.7; P = 0.013). The addition of IMH to a model of prognostic CMR parameters (ejection fraction, infarct size, and microvascular obstruction) led to net reclassification improvement of 0.42 (95% CI 0.11-0.73, P = 0.009). Conclusion: IMH assessed by T2* imaging may provide prognostic information that is incremental to other CMR markers of infarct severity and classical clinical risk factors. IMH could therefore be relevant as an important prognostic measure as well as therapeutic target when caring for patients after STEMI.
Aims: To evaluate the prognostic value of intramyocardial haemorrhage (IMH) depicted by T2* imaging for risk stratification in ST-elevation myocardial infarction (STEMI) patients in comparison with established cardiac magnetic resonance (CMR) prognosis markers. Methods and results: This multicentre study enrolled 264 patients reperfused within 12 h after symptom onset. CMR was performed within the first week after STEMI to assess left ventricular function and infarct characteristics including IMH. The primary endpoint was a composite of death, reinfarction, and new congestive heart failure (major adverse cardiac events, MACE) at 12 months. MACE occurred in 19 patients (7.2%) showing a higher prevalence of IMH when compared with patients without MACE (47% vs. 21%, P = 0.008). The presence of IMH (n = 60, 23%) was independently associated with MACE after adjusting for clinical risk factors [hazard ratio 2.7, 95% confidence intervals (CIs) 1.1-6.6; P = 0.032] or other CMR prognosis markers (hazard ratio 3.1, 95% CI 1.2-7.7; P = 0.013). The addition of IMH to a model of prognostic CMR parameters (ejection fraction, infarct size, and microvascular obstruction) led to net reclassification improvement of 0.42 (95% CI 0.11-0.73, P = 0.009). Conclusion:IMH assessed by T2* imaging may provide prognostic information that is incremental to other CMR markers of infarct severity and classical clinical risk factors. IMH could therefore be relevant as an important prognostic measure as well as therapeutic target when caring for patients after STEMI.
Authors: Maria Ferré-Vallverdú; Elena Sánchez-Lacuesta; Diego Plaza-López; José Luis Díez-Gil; Pilar Sepúlveda-Sanchis; Carolina Gil-Cayuela; Alicia Maceira-Gonzalez; Vicente Miró-Palau; Anastasio Montero-Argudo; Luis Martínez-Dolz; Begoña Igual-Muñoz Journal: Int J Cardiovasc Imaging Date: 2021-01-13 Impact factor: 2.357
Authors: Christina Christersson; Tomasz Baron; Frank Flachskampf; Lars Lindhagen; Bertil Lindahl; Agneta Siegbahn Journal: J Cardiovasc Transl Res Date: 2022-06-21 Impact factor: 4.132
Authors: Martin Reindl; Christina Tiller; Magdalena Holzknecht; Ivan Lechner; Benjamin Henninger; Agnes Mayr; Christoph Brenner; Gert Klug; Axel Bauer; Bernhard Metzler; Sebastian J Reinstadler Journal: JAMA Netw Open Date: 2020-06-01
Authors: Peter J McCartney; Annette M Maznyczka; Hany Eteiba; Margaret McEntegart; Keith G Oldroyd; John P Greenwood; Neil Maredia; Matthias Schmitt; Gerry P McCann; Timothy Fairbairn; Elisa McAlindon; Campbell Tait; Paul Welsh; Naveed Sattar; Vanessa Orchard; David Corcoran; Thomas J Ford; Aleksandra Radjenovic; Ian Ford; Alex McConnachie; Colin Berry Journal: J Am Coll Cardiol Date: 2020-03-31 Impact factor: 24.094
Authors: Dominik Jenča; Vojtěch Melenovský; Josef Stehlik; Vladimír Staněk; Jiří Kettner; Josef Kautzner; Věra Adámková; Peter Wohlfahrt Journal: ESC Heart Fail Date: 2020-12-14